Senior Director, Business Development, Alliance Management & Competitive Intelligence at Abata Therapeutics

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Advanced degree in Life Sciences, Business, or related field; MBA or PhD preferred
10+ years of experience in biotech/pharma business development, alliance management, and competitive intelligence, with a strong preference for oncology and autoimmune modalities
Proven track record of executing strategic partnerships, alliance management, and licensing deals
Strong understanding of biopharma R&D, clinical development, and regulatory pathways
Exceptional negotiation, communication, and leadership skills
Ability to thrive in a fast-paced, lean biotech environment
Willingness to travel domestically and/or internationally as required

Responsibilities

Proactively identify and evaluate strategic growth opportunities through potential collaboration partnerships that align with Janux’s pipeline, platform, and corporate objectives
Actively build market and competitive intelligence both to inform strategic decisions and the wider business development process
Coordinate the execution of strategic initiatives by developing and tracking implementation plans, ensuring focus and discipline to achieve organizational goals
Oversee alliance management activities, ensuring effective communication, issue resolution, and achievement of partnership objectives
Partner closely with internal stakeholders and external organizations to ensure effective governance, seamless execution, and strategic alignment across a dynamic portfolio of partnerships
Analyze market dynamics, competitor strategies, therapeutic landscapes, trial designs, and commercialization approaches to inform Janux’s portfolio prioritization and differentiation strategy
Monitor market trends, competitor pipelines, and regulatory landscapes to inform strategic business decisions
Deliver timely and actionable intelligence reports to executive leadership, highlighting market shifts, competitor moves, and partnership opportunities
Develop and maintain a competitive intelligence framework within oncology and immunology, particularly relating to Janux’s pipeline
Represent Janux at industry conferences, investor meetings, and strategic forums, and provide concise summaries of key insights to the organization

Skills

Business Development

Alliance Management

Competitive Intelligence

Strategic Partnerships

Market Analysis

Oncology

Immunology

Pipeline Evaluation

Governance

Stakeholder Management

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free